Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Co-administering Bivalent mRNA BNT162b2 Booster and Quadrivalent Influenza Vaccine
NCT06831786Phase 1Completed
- Sponsor
- Prince of Songkla University
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of tozinameran and Vaxigrip in coronavirus disease 2019 (COVID-19) and influenza (3 arms), sponsored by Prince of Songkla University. Primary endpoints: Geometric Mean of Interferon-gamma Response Against the SARS-CoV-2 Virus at 4 weeks and Geometric Mean of IgG Response Against the SARS-CoV-2 Virus at 4 weeks. Started Mar 2024; status: completed.
02
Drugs
tozinameranVaxigrip
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06831786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831786.